13 results
424B3
RLYB
Rallybio Corp
12 May 23
Prospectus supplement
4:50pm
with rare metabolic diseases.
Under the terms of the agreement, AbCellera and Rallybio will co-develop up to five rare disease therapeutic targets
8-K
EX-99.1
RLYB
Rallybio Corp
8 Aug 22
Rallybio Reports Second Quarter 2022 Financial Results
8:30am
and prevention of HPA-1a alloimmunization. These preclinical data establish both the potential and threshold exposure targets for prophylactic treatment
10-K
2021 FY
RLYB
Rallybio Corp
15 Mar 22
Annual report
4:31pm
therapeutic targets and product candidates that we believe have a high probability of success. Our ability to source these product candidates … disorder and expect to pursue additional small molecule targets in collaboration with Exscientia in additional joint ventures.
▪Expand our pipeline
8-K
EX-99.1
8v5sbty hxk6o7sta2j
7 Mar 22
MARCH 2022 TAKING A DEVASTATING DISEASE – AND DEVASTATING IT. We’re going there. Corporate Presentation
8:00am
424B4
drgsiyv7i
30 Jul 21
Prospectus supplement with pricing info
8:28am
S-1/A
EX-10.18
sugzhwm9en1lbn
22 Jul 21
IPO registration (amended)
4:04pm
S-1/A
EX-10.12
r2bkuxxipw 2pfzhbui
22 Jul 21
IPO registration (amended)
4:04pm
S-1/A
12dq2bnxwnzk4zppst7
22 Jul 21
IPO registration (amended)
4:04pm
S-1
spzdjnppwl1y4 apz2
2 Jul 21
IPO registration
4:28pm
DRS/A
7q85d67t h2gspab
7 Jun 21
Draft registration statement (amended)
12:00am
DRS
4ls5pk 1m
27 Apr 21
Draft registration statement
12:00am
- Prev
- 1
- Next